Novo Nordisk A/S (NOV.DE)

EUR 103.14

(-0.33%)

Market Cap (In EUR)

463.44 Billion

Revenue (In EUR)

232.26 Billion

Net Income (In EUR)

83.68 Billion

Avg. Volume

55.55 Thousand

Currency
EUR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
92.2-138.48
PE
-
EPS
-
Beta Value
0.165
ISIN
DK0062498333
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Lars Fruergaard Jorgensen
Employee Count
-
Website
https://www.novonordisk.com
Ipo Date
2001-06-07
Details
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.